Literature DB >> 26763540

Coronary intervention in 2015: Improvement of long-term outcomes after PCI.

Uwe Zeymer1.   

Abstract

Mesh：

Substances：

Year:  2016        PMID： 26763540     DOI： 10.1038/nrcardio.2015.204

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  9 in total

1.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Authors:  Laura Mauri; Dean J Kereiakes; Robert W Yeh; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Sharon-Lise T Normand; Eugene Braunwald; Stephen D Wiviott; David J Cohen; David R Holmes; Mitchell W Krucoff; James Hermiller; Harold L Dauerman; Daniel I Simon; David E Kandzari; Kirk N Garratt; David P Lee; Thomas K Pow; Peter Ver Lee; Michael J Rinaldi; Joseph M Massaro
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).

Authors:  Byeong-Keuk Kim; Myeong-Ki Hong; Dong-Ho Shin; Chung-Mo Nam; Jung-Sun Kim; Young-Guk Ko; Donghoon Choi; Tae-Soo Kang; Byoung-Eun Park; Woong-Chol Kang; Seung-Hwan Lee; Jung-Han Yoon; Bum-Kee Hong; Hyuck-Moon Kwon; Yangsoo Jang
Journal:  J Am Coll Cardiol       Date:  2012-09-19       Impact factor: 24.094

3.  Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.

Authors:  Michael Haude; Hüseyin Ince; Alexandre Abizaid; Ralph Toelg; Pedro Alves Lemos; Clemens von Birgelen; Evald Høj Christiansen; William Wijns; Franz-Josef Neumann; Christoph Kaiser; Eric Eeckhout; Soo Teik Lim; Javier Escaned; Hector M Garcia-Garcia; Ron Waksman
Journal:  Lancet       Date:  2015-10-12       Impact factor: 79.321

4.  2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Authors:  Stephan Windecker; Philippe Kolh; Fernando Alfonso; Jean-Philippe Collet; Jochen Cremer; Volkmar Falk; Gerasimos Filippatos; Christian Hamm; Stuart J Head; Peter Jüni; A Pieter Kappetein; Adnan Kastrati; Juhani Knuuti; Ulf Landmesser; Günther Laufer; Franz-Josef Neumann; Dimitrios J Richter; Patrick Schauerte; Miguel Sousa Uva; Giulio G Stefanini; David Paul Taggart; Lucia Torracca; Marco Valgimigli; William Wijns; Adam Witkowski
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

5.  Polymer-free Drug-Coated Coronary Stents in Patients at High Bleeding Risk.

Authors:  Philip Urban; Ian T Meredith; Alexandre Abizaid; Stuart J Pocock; Didier Carrié; Christoph Naber; Janusz Lipiecki; Gert Richardt; Andres Iñiguez; Philippe Brunel; Mariano Valdes-Chavarri; Philippe Garot; Suneel Talwar; Jacques Berland; Mohamed Abdellaoui; Franz Eberli; Keith Oldroyd; Robaayah Zambahari; John Gregson; Samantha Greene; Hans-Peter Stoll; Marie-Claude Morice
Journal:  N Engl J Med       Date:  2015-10-14       Impact factor: 91.245

Review 6.  Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials.

Authors:  Jacob A Udell; Marc P Bonaca; Jean-Philippe Collet; A Michael Lincoff; Dean J Kereiakes; Francesco Costa; Cheol Whan Lee; Laura Mauri; Marco Valgimigli; Seung-Jung Park; Gilles Montalescot; Marc S Sabatine; Eugene Braunwald; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2015-08-31       Impact factor: 29.983

7.  Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.

Authors:  Gérard Helft; Philippe Gabriel Steg; Claude Le Feuvre; Jean-Louis Georges; Didier Carrie; Xavier Dreyfus; Alain Furber; Florence Leclercq; Hélène Eltchaninoff; Jean-François Falquier; Patrick Henry; Simon Cattan; Laurent Sebagh; Pierre-Louis Michel; Albert Tuambilangana; Nadjib Hammoudi; Franck Boccara; Guillaume Cayla; Hervé Douard; Abdourahmane Diallo; Emmanuel Berman; Michel Komajda; Jean-Philippe Metzger; Eric Vicaut
Journal:  Eur Heart J       Date:  2015-09-12       Impact factor: 29.983

8.  Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial.

Authors:  Manel Sabaté; Salvatore Brugaletta; Angel Cequier; Andrés Iñiguez; Antonio Serra; Pilar Jiménez-Quevedo; Vicente Mainar; Gianluca Campo; Maurizio Tespili; Peter den Heijer; Armando Bethencourt; Nicolás Vazquez; Gerrit Anne van Es; Bianca Backx; Marco Valgimigli; Patrick W Serruys
Journal:  Lancet       Date:  2015-10-29       Impact factor: 79.321

9.  Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.

Authors:  Stephen G Ellis; Dean J Kereiakes; D Christopher Metzger; Ronald P Caputo; David G Rizik; Paul S Teirstein; Marc R Litt; Annapoorna Kini; Ameer Kabour; Steven O Marx; Jeffrey J Popma; Robert McGreevy; Zhen Zhang; Charles Simonton; Gregg W Stone
Journal:  N Engl J Med       Date:  2015-10-12       Impact factor: 91.245
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.